Novo Nordisk CEO Lars Fruergaard Jørgensen at a Senate Health, Education, Labor and Pensions (HELP) Committee hearing on Sept. 24, 2024 (Graeme Sloan/Sipa USA/Sipa via AP Images)
September 24, 2024 03:10 PM EDT
Pharma
FDA+

No­vo Nordisk CEO skep­ti­cal of PBM promis­es in Sen­ate hear­ing on weight loss drug prices

Nicole DeFeudis

Editor

Sen. Bernie Sanders (I-VT) told No­vo Nordisk CEO Lars Fruer­gaard Jør­gensen that three ma­jor phar­ma­cy ben­e­fit man­agers have agreed not to pe­nal­ize the com­pa­ny for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Wave rides new Phase 2 DMD da­ta as it sets sights on ac­cel­er­at­ed ap­proval

Sanofi hires Mike Quigley as next chief sci­en­tist, in­ter­nal memo says

Up­dat­ed: Gene ther­a­py mak­er blue­bird bio cuts costs again, lays off staff

Sam­sara adds three ven­ture part­ners to help steer and ad­vise port­fo­lio com­pa­nies

FDA ad­comm will re­ex­am­ine ap­proval of check­point in­hibitors in two can­cers based on key bio­mark­er

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times